AR and prostate cancer: Prior in vitro and in vivo studies in mouse models of hepatocellular carcinoma and prostate cancer have demonstrated that AR overexpression negatively attenuates anti-PD-L1, and that AR and PD-L1 dual blockade enhances the overall survival and T cell function [23,24].